An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis
- Registration Number
- NCT06849778
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Brief Summary
A phase 1, open-label, pharmacokinetic study of TS-172 in patients on hemodialysis
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 7
Inclusion Criteria
- Japanese male patients (outpatients) with chronic kidney disease receiving hemodialysis (HD or HDF) 3 times a week for at least 12 weeks prior to the screening test
- Patients aged >= 18 and < 75 years at the time of obtaining informed consent
Exclusion Criteria
- Patients with gastric or intestinal ulceration or a history of them within the past year prior to the date of initiation of treatment, or patients with inflammatory bowel disease or irritable bowel syndrome, or a history of these within the past 5 years prior to the date of initiation of treatment
- Patients scheduled for renal transplantation, home hemodialysis or change of dialysis facility (transfer or temporary dialysis at other hospital) during the study period
- Patients who frequently experience diarrhea (defined as Bristol Stool Scale score of 6 or higher)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description TS-172 TS-172 -
- Primary Outcome Measures
Name Time Method Concentration of unchanged form in plasma Day 1, 2, 8 and 9 Concentration of major metabolites in plasma Day 1, 2, 8 and 9
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the molecular target of TS-172 in hemodialysis patients with impaired renal function?
How does TS-172 compare to standard-of-care agents in managing complications of end-stage renal disease?
Which biomarkers predict TS-172 pharmacokinetic variability in patients undergoing hemodialysis?
What are the potential adverse events of TS-172 in hemodialysis patients and their management strategies?
What other investigational drugs from Taisho or competitors target similar pathways in hemodialysis patients?
Trial Locations
- Locations (1)
Taisho Pharmaceutical Co., Ltd selected site
🇯🇵Tokyo, Japan